Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE(®) (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25(th) EHA Annual Congress taking place June 11-21, 2020. The presentation will be made available on the event's website at www.ehaweb.org/congress/ on Friday, June 12 at 8:30 am CEST.

In this previously presented post-hoc analysis, 32 patients received TAVALISSE as a second-line therapy, and 78% (25/32) achieved >=1 platelet count of >=50,000/µL (without rescue therapy). Adverse events were manageable and consistent with those previously reported with fostamatinib.

Fostamatinib disodium hexahydrate is an oral drug designed to inhibit spleen tyrosine kinase (SYK), a key signaling component of the body's immune process that leads to platelet destruction in immune thrombocytopenia (ITP) and proposed red blood cell destruction in warm autoimmune hemolytic anemia (wAIHA). Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE (fostamatinib disodium hexahydrate) tablets and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. TAVALISSE is currently being investigated in a Phase 3 trial for the treatment of wAIHA, a rare, serious blood disorder for which there are no approved therapies.

Poster Presentation
Abstract #EP1625
Second-line Therapy for Immune Thrombocytopenia with the Spleen Tyrosine Kinase Inhibitor Fostamatinib
Dr. Nichola Cooper
Session Topic: 32. Platelets Disorders

About ITP
In patients with ITP, the immune system attacks and destroys the body's own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. People suffering with this disease may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. Current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs) and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

About AIHA
Autoimmune hemolytic anemia (AIHA) is a rare, serious blood disorder in which the immune system produces antibodies that result in the destruction of the body's own red blood cells. AIHA affects approximately 45,000 adult patients in the U.S. and can be a severe, debilitating disease. To date, there are no disease-targeted therapies approved for AIHA, despite the unmet medical need that exists for these patients. Warm AIHA (wAIHA), the most common form of AIHA, is characterized by the presence of antibodies that react with the red blood cell surface at body temperature.

TAVALISSE(®) (fostamatinib disodium hexahydrate) tablets is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information
Warnings and Precautions

    --  Hypertension can occur with TAVALISSE treatment. Patients with
        pre-existing hypertension may be more susceptible to the hypertensive
        effects. Monitor blood pressure every 2 weeks until stable, then
        monthly, and adjust or initiate antihypertensive therapy for blood
        pressure control maintenance during therapy. If increased blood pressure
        persists, TAVALISSE interruption, reduction, or discontinuation may be
    --  Elevated liver function tests (LFTs), mainly ALT and AST, can occur with
        TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase
        to >3 x upper limit of normal, manage hepatotoxicity using TAVALISSE
        interruption, reduction, or discontinuation.
    --  Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1%
        of patients treated with TAVALISSE. Monitor patients for the development
        of diarrhea and manage using supportive care measures early after the
        onset of symptoms. If diarrhea becomes severe (>=Grade 3), interrupt,
        reduce dose or discontinue TAVALISSE.
    --  Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile
        neutropenia occurred in 1% of patients. Monitor the ANC monthly and for
        infection during treatment. Manage toxicity with TAVALISSE interruption,
        reduction, or discontinuation.
    --  TAVALISSE can cause fetal harm when administered to pregnant women.
        Advise pregnant women the potential risk to a fetus. Advise females of
        reproductive potential to use effective contraception during treatment
        and for at least 1 month after the last dose. Verify pregnancy status
        prior to initiating TAVALISSE. It is unknown if TAVALISSE or its
        metabolite is present in human milk. Because of the potential for
        serious adverse reactions in a breastfed child, advise a lactating woman
        not to breastfeed during TAVALISSE treatment and for at least 1 month
        after the last dose.

Drug Interactions

    --  Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases
        exposure to the major active metabolite of TAVALISSE (R406), which may
        increase the risk of adverse reactions. Monitor for toxicities that may
        require a reduction in TAVALISSE dose.
    --  It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as
        concomitant use reduces exposure to R406.
    --  Concomitant use of TAVALISSE may increase concentrations of some CYP3A4
        substrate drugs and may require a dose reduction of the CYP3A4 substrate
    --  Concomitant use of TAVALISSE may increase concentrations of BCRP
        substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate
        drugs (eg, digoxin), which may require a dose reduction of the BCRP and
        P-gp substrate drug.

Adverse Reactions

    --  Serious adverse drug reactions in the ITP double-blind studies were
        febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which
        occurred in 1% of TAVALISSE patients. In addition, severe adverse
        reactions occurred including dyspnea and hypertension (both 2%),
        neutropenia, arthralgia, chest pain, diarrhea, dizziness,
        nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all
    --  Common adverse reactions (>=5% and more common than placebo) from FIT-1
        and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and
        AST increased, respiratory infection, rash, abdominal pain, fatigue,
        chest pain, and neutropenia.

Please see www.TAVALISSE.com for full Prescribing Information.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (800-332-1088).

TAVALISSE is a registered trademark of Rigel Pharmaceuticals, Inc.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE(®) (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and will be marketed in Europe under the name TAVLESSE(®) (fostamatinib).

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (wAIHA); a completed Phase 1 study of R835(1), a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552(1), a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

(1) The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Forward Looking Statements
This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, the commercial success of TAVALISSE in the U.S.; Rigel's ability to broaden its pipeline of assets; future drug development plans; the potential for the results of ongoing clinical trials; and the market potential for Rigel's marketed products and product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "potential," "may," "expects" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of TAVALISSE; risks that the FDA, EMA or other regulatory authorities may make adverse decisions regarding fostamatinib; risks that TAVALISSE clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that TAVALISSE may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. In addition, the COVID-19 pandemic may result in further delays in Rigel's studies, trials and sales, or impact Rigel's ability to obtain supply of TAVALISSE. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-poster-highlighting-tavalisse-at-the-virtual-edition-of-the-25th-european-hematology-association-eha-annual-congress-301074137.html

SOURCE Rigel Pharmaceuticals, Inc.